Annual report
4885.TEDINET S100UA72
Period2023-06-01 → 2024-05-31
Filed2024-08-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 95
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.4bn | 2023-06-01 → 2024-05-31 | Standalone | Net sales |
| Revenue | ¥6.3bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥5.7bn | 2021-06-01 → 2022-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.9bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥422m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Operating income | ¥369m | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Ordinary income | ¥428m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥351m | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥423m | 2021-06-01 → 2022-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥339m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥272m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥278m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥469m | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥351m | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Net income (owners) | ¥32m | 2019-06-01 → 2020-05-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥330m | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | ¥256m | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥456m | 2021-06-01 → 2022-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥181m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥34m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.1bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥4.9bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥4.8bn | at 2022-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.6bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.8bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥2.8bn | at 2024-05-31 | Standalone | Liabilities |
| Total liabilities | ¥3.0bn | at 2023-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.3bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-05-31d | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥252m | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2024-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥853m | at 2023-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2024-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥853m | at 2023-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥865m | at 2022-05-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2021-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥881m | at 2020-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥638m | 2023-06-01 → 2024-05-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥317m | 2022-06-01 → 2023-05-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥525m | 2021-06-01 → 2022-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥488m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥89m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥232m | 2023-06-01 → 2024-05-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥162m | 2022-06-01 → 2023-05-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥176m | 2021-06-01 → 2022-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥58m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥137m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥210m | 2023-06-01 → 2024-05-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥172m | 2022-06-01 → 2023-05-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥484m | 2021-06-01 → 2022-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥311m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥42m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥83.42 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.94 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.79 | 2021-06-01 → 2022-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.24 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.75 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.16 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥81.86 | 2023-06-01 → 2024-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.12 | 2022-06-01 → 2023-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥112.56 | 2021-06-01 → 2022-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.97 | 2020-06-01 → 2021-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-06-01 → 2023-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2021-06-01 → 2022-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-06-01 → 2021-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥571.26 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥487.25 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥450.37 | at 2022-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥363.93 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥101.92 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 44.9% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.7% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.0% | at 2022-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 5.3% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 15.8% | 2023-06-01 → 2024-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.3% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.3% | 2021-06-01 → 2022-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 22.8% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.0% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,095,500 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2022-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 775,000 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 205 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 205 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 197 | at 2022-05-31d | Standalone | Number of employees |
| Employees | 195 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 196 | at 2020-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 53
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2024-05-31 | ¥1.6bn |
| Chemical Products Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥77m |
| Chemical Products Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥56m |
| Chemical Products Businessreportable segment | employees | at 2024-05-31 | 54 pure |
| Chemical Products Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥2.3bn |
| Chemical Products Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥2.3bn |
| Chemical Products Businessreportable segment | segment assets | at 2024-05-31 | ¥1.1bn |
| Chemical Products Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥16m |
| Healthy Food Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥15m |
| Healthy Food Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥27m |
| Healthy Food Businessreportable segment | employees | at 2024-05-31 | 19 pure |
| Healthy Food Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥834m |
| Healthy Food Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥834m |
| Healthy Food Businessreportable segment | segment assets | at 2024-05-31 | ¥473m |
| Healthy Food Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥38m |
| Pharmaceutical Businessreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥198m |
| Pharmaceutical Businessreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥54m |
| Pharmaceutical Businessreportable segment | employees | at 2024-05-31 | 53 pure |
| Pharmaceutical Businessreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥3.3bn |
| Pharmaceutical Businessreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥3.3bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2024-05-31 | ¥1.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥476m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-06-01 → 2024-05-31 | ¥289m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-06-01 → 2024-05-31 | ¥136m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2024-05-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2024-05-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-05-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2024-05-31 | ¥422m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥1.3bn |
| Chemical Products Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥37m |
| Chemical Products Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥50m |
| Chemical Products Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥2.1bn |
| Chemical Products Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥2.1bn |
| Chemical Products Businessreportable segment | segment assets | at 2023-05-31 | ¥1.2bn |
| Chemical Products Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥50m |
| Healthy Food Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥17m |
| Healthy Food Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥28m |
| Healthy Food Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥658m |
| Healthy Food Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥658m |
| Healthy Food Businessreportable segment | segment assets | at 2023-05-31 | ¥395m |
| Healthy Food Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥120m |
| Pharmaceutical Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥128m |
| Pharmaceutical Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥45m |
| Pharmaceutical Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥3.5bn |
| Pharmaceutical Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥3.5bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2023-05-31 | ¥2.0bn |
| Pharmaceutical Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥539m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥181m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥122m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | ¥369m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,231
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 131000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0329 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 116950 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0294 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 80800 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0203 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 80000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0201 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 75000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0189 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 75000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0189 | |
| Number of shares held | CurrentYearInstant | 1909264 | |
| Shareholding ratio | CurrentYearInstant | 0.4801 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 119600 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 3971400 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 39714 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 4500 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 4095500 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 39714 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 119600 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 119600 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0292 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 119600 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 119600 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0292 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 87467000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 22 | |
| Number of male directors and other officers | FilingDateInstant | 7 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.222 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000AokiJunichiMember | 342650 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000IuchiSatoshiMember | 52550 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000InokuchiHirotoshiMember | 40500 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000SakayaTakashiMember | 9294 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000NakamuraHiroshiMember | 41200 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000ToriiRyokoMember | 850 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000TakahashiSatoruMember | 7150 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000YamamotoHiroomiMember | 2450 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36350-000NodaKaoruMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 496644 | |
| Audit fees reporting company | Prior1YearDuration | 23700000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 26000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |